CRDF news

Cardiff Oncology amended its certificate of incorporation on Oct. 22, 2026, increasing the number of authorized common shares to 300 million. This authorization supports future share issuance for potential business development.

Cardiff Oncology filed a warrant agreement related to its July 2026 securities purchase. The document outlines the terms for investors to purchase common stock starting in 2027.

Cardiff Oncology released interim results from its randomized Phase 2 CRDF-004 trial evaluating onvansertib combined with standard chemotherapy and bevacizumab for first-line RAS-mutated metastatic colorectal cancer. The trial data may impact the company's clinical development pathway and commercial…